腹膜透析作为既往血液透析后的首选与次选方案：一项长期评估

Peritoneal Dialysis as a First versus Second Option after Previous Haemodialysis: A Very Long-Term Assessment.

作者信息

Barone Roberto José, Cámpora María Inés, Gimenez Nélida Susana, Ramirez Liliana, Panese Sergio Alberto, Santopietro Mónica

机构信息

Peritoneal Dialysis Program, Hurlingham Renal Therapy Services, 1431 Buenos Aires, Argentina.

出版信息

Int J Nephrol. 2014;2014:693670. doi: 10.1155/2014/693670. Epub 2014 Nov 20.

UNLABELLED

For renal replacement therapy, overall survival is more important than the choice of currently available individual therapy. Objectives. To compare patients and technique survival on peritoneal dialysis as first treatment (PDF) versus after previous haemodialysis (HDPD) and other indicators of follow-up. Methods. We prospectively studied 110 incident patients, during the period from August 4, 1993, to June 30, 2012, for patients and technique survival (Kaplan-Meier) (log rank P < 0.05). Results. Groups: (A) PDF: 37 patients, 24 females, age: 52.2 ± 14.9 years old, time at risk: 2123 patient-months (p/m), mean: 57 ± 42 months; (B) HDPD: 73 patients, 42 females, age: 52.45 ± 14.7 years old, time in haemodialysis: 3569.2 (p/m), range: 3-216 months, mean: 49 ± 45 months, time at risk in PD: 3700 (p/m), mean: 51 ± 49 months. Patients' survival: (A) PDF: 100%, 76.6%, 65.6%, and 19.7%; (B) HDPD: 95.4%, 65.6%, 43%, and 43% at 12, 60, 120, and 144 months, respectively, P = 0.34.

TECHNIQUE

(A) PDF: 100%, 90%, 59.8%, and 24%; (B) HDPD: 94%, 75%, 32%, and 32% at 12, 60, 120, and 144 months, respectively, P = 0.40. Conclusions. Comparable patient and technique survival were observed. Peritoneal dialysis enables a greater extension of renal replacement therapy for patients with serious difficulties continuing with haemodialysis.

未标注

对于肾脏替代治疗，总体生存率比目前可用的个体治疗选择更为重要。目的。比较首次接受腹膜透析（PDF）与先前接受血液透析（HDPD）后的患者生存率和技术生存率以及其他随访指标。方法。我们对1993年8月4日至2012年6月30日期间的110例新发病例患者进行了前瞻性研究，以观察患者生存率和技术生存率（Kaplan-Meier法）（对数秩检验P<0.05）。结果。分组：（A）PDF组：37例患者，24例女性，年龄：52.2±14.9岁，风险时间：2123患者月（p/m），平均：57±42个月；（B）HDPD组：73例患者，42例女性，年龄：52.45±14.7岁，血液透析时间：3569.2（p/m），范围：3 - 216个月，平均：49±45个月，腹膜透析风险时间：3700（p/m），平均：51±49个月。患者生存率：（A）PDF组：在12、60、120和144个月时分别为100%、76.6%、65.6%和19.7%；（B）HDPD组：在12、60、120和144个月时分别为95.4%、65.6%、43%和43%，P = 0.34。

技术生存率

（A）PDF组：在12、60、120和144个月时分别为100%、90%、59.8%和24%；（B）HDPD组：在12、60、120和144个月时分别为94%、75%、32%和32%，P = 0.40。结论。观察到患者生存率和技术生存率具有可比性。腹膜透析能够为继续进行血液透析存在严重困难的患者提供更长时间的肾脏替代治疗。